PT - JOURNAL ARTICLE AU - Shin, Andrea AU - Xing, Yue AU - Waseem, Mohammed Rayyan AU - Siwiec, Robert AU - James-Stevenson, Toyia AU - Rogers, Nicholas AU - Bohm, Matthew AU - Wo, John AU - Lockett, Carolyn AU - Gupta, Anita AU - Gupta, Anita AU - Kadariya, Jhalka AU - Toh, Evelyn AU - Anderson, Rachel AU - Xu, Huiping AU - Gao, Xiang TI - Microbiota-Short Chain Fatty Acid Relationships and Microbial Substrate Preferences Vary Across the Spectrum of Irritable Bowel Syndrome (IBS) AID - 10.1101/2024.01.31.24302084 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.31.24302084 4099 - http://medrxiv.org/content/early/2024/02/01/2024.01.31.24302084.short 4100 - http://medrxiv.org/content/early/2024/02/01/2024.01.31.24302084.full AB - Objective Identifying microbial targets in irritable bowel syndrome (IBS) is challenged by dynamic microbiota-metabolite-host interactions. We aimed to assess microbial features associated with short chain fatty acids (SCFA) and determine if features were related to IBS symptoms, subtypes, and endophenotypes.Design We performed an observational study of stool microbial metagenomes, stool SCFA, and IBS traits (stool form, stool bile acids, and colonic transit) in patients with IBS (IBS with constipation [IBS-C] IBS with diarrhea [IBS-D]) and healthy controls. We analyzed associations of microbiome composition with stool SCFA to identify microbe-SCFA relationships that were shared and distinct across groups. We compared gut microbiome-encoded potential for substrate utilization across groups and within a subset of participants selected by stool characteristics. In IBS-D, we compared stool microbiomes of patients with and without bile acid malabsorption (BAM).Results Overall stool microbiome composition and abundances of individual taxa differed between groups. Increased abundances of several bacterial species were observed in IBS-D including Dorea sp. CAG:317.. Microbes-SCFA relationships varied across groups after accounting for transit and bile acids. Significant microbe-SCFA were common in IBS-D and several SCFA-producing species were inversely correlated with SCFA. Among participants selected by stool form characteristics, functional profiling demonstrated differential abundances of microbial genes/pathways for SCFA metabolism and degradation of carbohydrates and mucin across groups. SCFA-producing taxa were reduced in IBS-D with BAM.Conclusion Microbe-SCFA associations differ across IBS subtypes and traits. Altered substrate preferences offer insights into functional microbiome traits and could be used as novel microbial IBS biomarkers.KEY MESSAGES What is already known on this topic: The intestinal microbiota and its metabolites (e.g., short chain fatty acids [SCFA]) modulate irritable bowel syndrome (IBS) pathophysiology.What this study adds: We studied microbe-SCFA associations across IBS subtypes and endophenotypes to demonstrate (1) the intestinal microbiome plays distinct roles across IBS subtypes, (2) microbial substrate preferences vary between IBS subtypes and influences stool form, and (3) microbe-SCFA patterns may reveal key taxa that underlie shared and distinct microbial mechanisms across the IBS spectrum.How this study might affect research, practice or policy: Findings demonstrate that structural and functional features of the intestinal microbiome may represent unbiased microbial biomarkers for clinical and mechanistic IBS subtypes. Further study of these putative microbial targets as well as their interactions with diet- and host-specific traits should be pursued to develop individualized microbiome-based approached to IBS management.Competing Interest StatementAS serves on Ardelyx Scientific Communications Advisory Board for irritable bowel syndrome with constipation.Clinical Protocols https://www.clinicaltrials.gov/ Funding StatementAS is supported by NIDDK K23DK122015 and R03DK132446.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Indiana University Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesMicrobiome sequencing reads are deposited into NCBI with accession number SUB13882354. The data that support the findings of this study are available upon reasonable request from the corresponding author.ALRadditive log-ratioBAMbile acid malabsorptionCTTcolonic transit timegDNAgenomic DNAGIgastrointestinalGLMgeneralized linear modelGMMgut metabolic moduleIBSirritable bowel syndromeIBS-DIBS with diarrheaIBS-CIBS with constipationKEGGKyoto Encyclopedia of Genes and GenomicsKOKEGG OrthogroupLC-MSliquid chromatography-mass spectrometrySCFAshort chain fatty acids